CVC Capital Partners ("CVC") today announced that funds advised by CVC have finalised the sale of part of their stake in Jintian Pharmaceutical Group Ltd ("Jintian"), a leading pharmaceutical retailer and distributor in Northeast China, which is listed on the Hong Kong Stock Exchange.
Funds advised by CVC have sold 185,500,000 shares at the price of HK$3.29 per share, and retain a stake of 6.9% in the business.
CVC funds made an initial investment in Jintian in October 2011, acquiring a 24.2% stake. The company successfully completed its listing on the Hong Kong Stock Exchange in December 2013.
Francis Leung, Managing Partner and Chairman of Greater China for CVC, commented: "We are pleased that CVC funds invested and remain invested in Jintian. The recent sale of part of the CVC funds' investment in the business is in line with our usual process of managing CVC fund investments and has realised a solid return for our investors. CVC will continue to support the management of Jintian in executing its strategic objectives."
CVC Credit supports the acquisition of Rentokil Workwear France by H.I.G. Capital
CVC announces sale of majority of CVC Capital Partners VII’s stake in Tipico to Banijay Group
CVC DIF and Jersey Telecom to acquire Manx Telecom Group, the integrated incumbent digital-infrastructure platform on the Isle of Man
Partners Group and CVC agree partnership to drive next phase of growth at International Schools Partnership, a leading global K-12 school platform
CVC DIF to divest Portuguese highway concessions Norte Litoral and Algarve to Igneo Infrastructure Partners
CVC DIF to acquire CARMA Corp., a leading Canadian submetering and essential building services platform
KKR agrees to acquire NewDay's consumer credit portfolio from Cinven and CVC